Atossa shares jump 55% after 'poison pill' announcement; but who is suitor?
This article was originally published in Clinica
Breast cancer diagnostic firm Atossa Genetics has adopted a so-called “poison pill” strategy, aimed to deflect hostile takeovers, and seen its stock climb nearly 55%. The firm did not give any details of who might be trying to buy it, and was not available for comment as Clinica went to press. But nonetheless, its share price closed at $1.91 on 22 May, up from $1.24 the previous day.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.